Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Health-Related Quality of Life of Patients with Intermediate Hepatocellular Carcinoma after Liver Resection or Transcatheter Arterial Chemoembolization

  • Xie, ZR (Liver Surgery, West China Hospital, Sichuan University) ;
  • Luo, YL (Liver Surgery, West China Hospital, Sichuan University) ;
  • Xiao, FM (Liver Surgery, West China Hospital, Sichuan University) ;
  • Liu, Q (Liver Surgery, West China Hospital, Sichuan University) ;
  • Ma, Y (Liver Surgery, West China Hospital, Sichuan University)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of our present study was to compare quality of life (QoL) between intermediate-stage (BCLC-B) HCC patients who had undergone either liver resection or transcatheter arterial chemoembolization (TACE). Materials and Methods: A total of 102 intermediate-stage HCC patients participated in our study, including 58 who had undergone liver resection and 44 who had undergone TACE. Baseline demographic characteristics, tumor characteristics, and long-term outcomes, such as tumor recurrence, were compared and analyzed. QoL was assessed using the Short Form (SF)-36 health survey questionnaire with the mental and physical component scales (SF-36 MCS and PCS). This questionnaire was filled out at HCC diagnosis and 1, 3, 6, 12, 24 months after surgery. Results: For the preoperative QoL evaluation, the 8 domains related to QoL were comparable between the two groups. The PCS and MCS scores were significantly decreased in both the TACE and resection groups at1 month after surgery, and this decrease was greater in the resection group. These scores were significantly lower in the resection group compared with the TACE group (P<0.05). However, these differences disappeared at 3 and 6 months following surgery. One year after surgery, the resection group showed much higher PCS scores than the TACE patients (P=0.018), and at 2 years after surgery, the PCS and MCS scores for the resection group were significantly higher than those for the TACE group (P<0.05). Eleven patients (19.0%) in the resection group and 17 (38.6%) in the TACE group suffered HCC recurrence (P<0.05). Univariate and multivariate analyses indicated that tumor recurrence (HR=1.211, 95%CI: 1.086-1.415, P=0.012) was a significant risk factor for poorpostoperative QoL in the HCC patients.Conclusions: Due to its effects on reducing HCC recurrence and improving long-term QoL, liver resection should be the first choice for the treatment of patients with intermediate-stage HCC.

Keywords

References

  1. Jemal A, Bray F, Center MM, et al (2011). CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  2. Maluccio M, Covey A (2012). Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 62, 394-9. https://doi.org/10.3322/caac.21161
  3. Bruix J, Gores GJ, Mazzaferro V (2014). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 63, 844-55. https://doi.org/10.1136/gutjnl-2013-306627
  4. Zuo CH, Xia M, Liu JS, et al (2015). Transcatheter arterial chemoembolization combined with interferon-alpha is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev, 16, 245-51. https://doi.org/10.7314/APJCP.2015.16.1.245
  5. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
  6. Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6. https://doi.org/10.7314/APJCP.2014.15.2.703
  7. Marrero JA, Fontana RJ, Barrat A, et al (2005). Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatol, 41, 707-16. https://doi.org/10.1002/hep.20636
  8. Zhong JH, Ke Y, Gong WF, et al (2014). Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg, 260, 329-40. https://doi.org/10.1097/SLA.0000000000000236
  9. Jianyong L, Lunan Y, Wentao W, et al (2014). Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore), 93, 180. https://doi.org/10.1097/MD.0000000000000180
  10. Slevin ML (1992). Quality of life: philosophical question or clinical reality? BMJ, 305, 466-9. https://doi.org/10.1136/bmj.305.6851.466
  11. Han KT, Park EC, Kim SJ, et al (2014). Factors affecting the quality of life of Korean cancer survivors who return to the workplace. Asian Pac J Cancer Prev, 15, 8783-8. https://doi.org/10.7314/APJCP.2014.15.20.8783
  12. Langenhoff BS, Krabbe PF, Wobbes T, et al (2001). Quality of life as an outcome measure in surgical oncology. Br J Surg, 88, 643-52. https://doi.org/10.1046/j.1365-2168.2001.01755.x
  13. Scurtu R, Groza N, Otel O, et al (2005). Quality of life in patients with esophagojejunal anastomosis after total gastrectomy for cancer. Rom J Gastroenterol, 14, 367-72.
  14. Diouf M, Bonnetain F, Barbare JC, et al (2015). Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist, 20, 62-71. https://doi.org/10.1634/theoncologist.2014-0175
  15. Diouf M, Filleron T, Barbare JC, et al (2013). The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol, 58, 509-21. https://doi.org/10.1016/j.jhep.2012.11.019
  16. Yeo W, Mo FK, Koh J, et al (2006). Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol, 17, 1083-9. https://doi.org/10.1093/annonc/mdl065
  17. Gandhi S, Khubchandani S, Iyer R (2014). Quality of life and hepatocellular carcinoma. J Gastrointest Oncol, 5, 296-317.
  18. Fan SY, Eiser C, Ho MC (2010). Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol, 8, 559-64. https://doi.org/10.1016/j.cgh.2010.03.008
  19. Bruns H, Kratschmer K, Hinz U, et al (2010). Quality of life after curative liver resection: a single center analysis. World J Gastroenterol, 16, 2388-95. https://doi.org/10.3748/wjg.v16.i19.2388
  20. Mise Y, Satou S, Ishizawa T, et al (2014). Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg, 38, 958-67. https://doi.org/10.1007/s00268-013-2342-9
  21. Xing M, Webber G, Prajapati HJ, et al (2015). Preservation of quality of life with doxorubicin drug eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: longitudinal prospective study. J Gastroenterol Hepatol, [Epub ahead of print].
  22. Wang YB, Chen MH, Yan K, et al (2007). Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res, 16, 389-97. https://doi.org/10.1007/s11136-006-9133-9
  23. Toro A, Pulvirenti E, Palermo F, et al (2012). Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol, 21, 23-30. https://doi.org/10.1016/j.suronc.2010.07.008
  24. Li L, Wang H, Shen Y (2002). Development and psychometric tests of a Chinese version of the SF-36 Health Survey Scales. Zhonghua yu fang yi xue za zhi, 36, 109-13.
  25. Jin S, Yan L, Li B, et al (2010). Quality of life and psychologic distress of recipients after adult living-donor liver transplantation (LDLT)-A study from mainland China. Transplant Proc, 42, 2611-6. https://doi.org/10.1016/j.transproceed.2010.04.062
  26. Zhang T, Zeng Y, Huang J, et al (2014). Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: a single-center experience. J Surg Res, 191, 370-8. https://doi.org/10.1016/j.jss.2014.03.048
  27. Jiang L, Lei JY, Wang WT, et al (2014). Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE. J Gastrointest Surg, 18, 1125-30. https://doi.org/10.1007/s11605-014-2508-2
  28. Mancuso A, Mazzola A, Cabibbo G, et al (2015). Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. Dig Liver Dis, 47, 324-30 https://doi.org/10.1016/j.dld.2015.01.001
  29. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9. https://doi.org/10.7314/APJCP.2013.14.12.7367
  30. Schipper H, Clinch J, McMurray A, et al (1984). Measuring the quality of life of cancer patients: the functional living indexcancer: development and validation. J Clin Oncol, 2, 472-83. https://doi.org/10.1200/JCO.1984.2.5.472
  31. Steel JL, Geller DA, Robinson TL, et al (2014). Health-related quality of life as a prognostic factor in patients with advanced cancer. Cancer, 120, 3717-21. https://doi.org/10.1002/cncr.28902
  32. Martin RC, Eid S, Scoggins CR, et al (2007). Health-related quality of life: return to baseline after major and minor liver resection. Surgery, 142, 676-84. https://doi.org/10.1016/j.surg.2007.04.026
  33. Poon RT, Fan ST, Yu WC, et al (2001). A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg, 136, 693-9. https://doi.org/10.1001/archsurg.136.6.693

Cited by

  1. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.473
  2. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization vol.40, pp.10, 2017, https://doi.org/10.1007/s00270-017-1681-6